 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Companys Board of Directors. Dr. Perlman will also serve as a member of Arcuss Nominating and Corporate Governance Committee. Drs. Perlman and Quigley both have outstanding track records of success working in innovative and intensely comp 